Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Allena Pharmaceuticals, Inc. logo

    Allena Pharmaceuticals, Inc.

    N/A

    US$12200.0

    N/A

    N/A

    Transparent research score

    MaveScore

    A research prioritization score from 0 to 100. It is model output for watchlist review, not personalized financial advice.

    0 Low confidence Low
    Fundamentals Dec 31, 2022
    Price Updating
    Confidence Low

    Stored data quality

    Freshness and coverage checks

    Mavefund is missing enough stored company inputs that this score should be treated as preliminary research only.

    6/16 Limited stored snapshot
    Fundamental period Dec 31, 2022 1257 days old
    Price snapshot Updating Refreshing
    Input coverage 6/16 Stored fields powering this model output
    Confidence impact 10 gaps Missing fields reduce confidence and can limit signal detail

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    0/35 Weak

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    0/25 Weak

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    0/15 Weak

    Momentum

    Momentum needs recent 3-month or 6-month price-change data.

    0/15 Needs Data

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength rewards durable profitability, margins, and positive free cash flow.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include EPS rank, ROE rank, net margin rank, share-count rank, leverage rank, net margin, gross margin, latest price, 3-month price change, 6-month price change.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Allena Pharmaceuticals, Inc. Overview

    Industry: Biotechnology

    Sector: Healthcare

    Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

    Allena Pharmaceuticals, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Allena Pharmaceuticals, Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    Allena Pharmaceuticals, Inc. Competitors

    Allena Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Allena Pharmaceuticals, Inc.

    N/A

    US$12200.0

    N/A

    N/A